Rivista di formazione e aggiornamento professionale del pediatra e del medico di base, fondata nel 1982. In collaborazione con l'Associazione Culturale Pediatri.
Login Abbonamenti Pubblicazioni Carrello Registrazione Perché registrarsi? Contatti

Hepacivirus

4 articoli — 1997-2025

RI Casi indimenticabili
Due fratelli con infezione da epatite C: i farmaci DAA

Mainetti M, Turlà G, Rametta G, Marchetti F.

2025/9 — pag. 598-600 — DOI

Two brothers, aged 9 and 13, born to a mother with hepatitis C (genotype 1b), tested positive for HCV. Both were asymptomatic and in good general condition, only the older brother showed mildly elevated transaminases. HCV-RNA levels were high in both...

RI Farmacoriflessioni
Cosa deve sapere oggi il pediatra del trattamento dell’epatite C nell’era dei nuovi farmaci antivirali?

Veraldi S, Maggiore G.

2024/5 — pag. 303-307 — DOI

The treatment of hepatitis C virus (HCV) infection with the new direct-acting antivirals (DAAs) has dramatically modified the natural history of the HCV-related disease, eradicating the virus in over 90% of treated patients, with negligible collatera...

RI Ricerca
Accesso libero
La trasmissione perinatale dell’HCV

M. Resti e coll.

1998/8 — pag. 529-534

Mother-to-child HCV transmission is an emergent problem, but risk factors for vertical transmission are still not completely known. Previous reports have shown extremely different transmission rates ranging from 5.6% to 36%. The importance of HI...

RI Problemi correnti
Accesso libero
Uso di immunoglobuline e rischio di epatite C

G. Bartolozzi

1997/6 — pag. 369-370

Recently HCV infection has been reported in association with administration of parenteral immunoglobulin. In some patients HCV infection was associated with severe, acute course, attributable to host factors, such as immunodeficiencies. Many of...